NCT00002965View on ClinicalTrials.gov

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 1997

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions
Brain and Central Nervous System Tumors
Interventions
BIOLOGICAL

Recombinant Interferon Alfa (INF alpha)

Subcutaneous injection Monday through Friday for 8 weeks.

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00002965 - Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas | Biotech Hunter | Biotech Hunter